MONMOUTH JUNCTION, N.J., June 26 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) announced today that it has entered into a multi-product development and licensing agreement with Novartis (NYSE: NVS) for the MicroDose proprietary dry powder inhaler (DPI). This agreement follows the successful completion of an exploratory study performed with the MicroDose DPI.